Skip to main content

Table 1 Baseline characteristics

From: Safety and efficacy of protease inhibitor based combination therapy in a single-center “real-life” cohort of 110 patients with chronic hepatitis C genotype 1 infection

  All patients Telaprevir Boceprevir
(N = 102) (N = 65) (N = 37)
  N (%); median (range) N (%); median (range) N (%); median (range)
Male sex 63 (62%) 43 (66%) 20 (54%)
Exclusion criteria for appropriate phase III trials 65 (64%) 42 (65%) 23 (62%)
Treatment naïve 47 (46%) 23 (35%) 24 (65%)
Treatment experienced 55 (54%) 42 (65%) 13 (35%)
Relapse 25 (25%) 18 (28%) 7 (19%)
Null/partial response 15 (15%) 13 (20%) 2 (5%)
Breakthrough 6 (6%) 5 (8%) 1 (3%)
Discontinuation § 5 (5%) 3 (5%) 2 (5%)
Unknown outcome 4 (4%) 3 (5%) 1 (3%)
DAA experienced 10 (10%) 9 (14%) 1 (3%)
RVR 38 (37%) 21 (32%) 17 (46%)
Genotype    
Genotype 1a 39 (38%) 20 (31%) 19 (51%)
Genotype 1b 53 (52%) 37 (57%) 16 (43%)
No subtype provided 9 (9%) 7 (11%) 2 (5%)
Unknown 1 (1%) 1 (2%) 0
IL28B (N = 70)    
C/C 16 (24%) 10 (20%) 6 (29%)
C/T 42 (60%) 32 (65%) 10 (48%)
T/T 12 (17%) 7 (14%) 5 (24%)
Stage of fibrosis (N = 92)    
No or mild fibrosis (F0-F2) 51 (55%) 32 (49%) 19 (59%)
Bridging fibrosis (F3) 12 (13%) 6 (10%) 6 (19%)
Liver cirrhosis 29 (32%) 22 (37%) 7 (22%)
Hemoglobin [g/dl] 14.7 (10.3-18.8) 14.7 (11.1-18.8) 14.6 (10.3-17.6)
Leukocytes [x10^9/l] 6.1 (2.7-13.1) 5.9 (2.7-13.1) 6.3 (3.9-12.4)
Platelets [x10^9/l] 188 (48–377) 180 (48–377) 203 (67–338)
ASAT [U/l] 50.5 (16–328) 52 (16–328) 44 (19–156)
ALAT [U/l] 75.5 (16–271) 87 (16–271) 72 (19–227)
γGT [U/l] 66.5 (25–1274) 67 (25–1274) 62 (25–217)
Bilirubin [mg/dl] 0.5 (0.2-2.2) 0.6 (0.3-2.2) 0.5 (0.2-1.4)
Albumin [g/l] 40 (25–50) 40 (25–47) 39 (30–50)
Prothrombin time [INR] 1.00 (0.90-3.29) 1.02 (0.90-3.29) 1.00 (0.92-2.33)
Creatinine [mg/dl] 0.8 (0.5-5.8) 0.8 (0.5-1.1) 0.8 (0.5-5.8)
Viral load undetectable at    
EOT 82 (80%) 51 (78%) 31 (84%)
SVR12 62 (61%) 40 (62%) 22 (59%)
  1. [N = number; DAA = direct acting antivirals; RVR = rapid virological response; IL28B = interleukin-28B polymorphism; EOT = end of treatment; SVR12 = sustained virological response 12 weeks after last ribavirin dose; § = cessation of prior therapy due to side-effects].